Gut Health and Side Effects from Breast Cancer Hormone Treatment
Part of Cancer, Skin clinical trials.
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer confirmed by biopsy that is hormone-receptor positive (ER/PR positive) and HER2 negative
- Your doctor has planned to treat you with abemaciclib plus hormone therapy as standard care
- You are at least 18 years old and able to give written consent
- You are willing to provide stool samples at the start and during your cancer treatment
- You are generally well enough to tolerate treatment (ECOG performance score 0–2, meaning you can do light activities)
- You are not pregnant, breastfeeding, or currently in another experimental cancer trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how abemaciclib (Verzenio) affects the bacteria in your gut (the microbiome). If you have a certain type of breast cancer and are starting this treatment, researchers want to understand why it works the way it does.
This trial tests whether a special probiotic supplement (good bacteria) can reduce belly discomfort caused by abemaciclib, a hormone therapy drug for early breast cancer. You would take the supplement alongside your cancer treatment to see if it helps with stomach side effects.
This trial is for people with hormone receptor-positive breast cancer who are at high risk of recurrence. It looks at how the body processes abemaciclib, a targeted therapy, and whether that affects severe diarrhea, a common side effect.
This study looks at how changing your diet during chemotherapy affects side effects and your body's energy use. It involves providing stool samples to study gut bacteria.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.